Net sales rose to SEK 13.0m and operating loss narrowed to SEK -77.2m in 2024, driven by US expansion, cost reductions, and a SEK 90m rights issue. FDA review for a new big toe implant is ongoing, with further US growth and new product launches planned for 2025.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.